Shire PLC the global specialty biopharmaceutical company, will announce third quarter 2007 earnings on Thursday 1 November 2007.
Live conference call for investors:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:30 GMT/10:30 ET.
Please RSVP ssalah@shire.com (T: +44(0)1256-894-160) for this conference call.
http://www.shire.com/shire/InvestorRelations/events.jsp?tn=2&m1=33
Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:
http://www.shire.com/shire/InvestorRelations/events.jsp?tn=2&m1=33
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: http://www.shire.com.
CONTACT: For further information please contact: Investor Relations
Souheil Salah (Rest of the World): +44-1256-894-160; Heidi Wunder (North
America): +1-484-595-8970
